Corvus pill shows promise in early-stage eczema trial
statnews.com • • business
Key Points:
- Corvus Pharmaceuticals announced updated results from an early-stage study of soquelitinib, an oral treatment for eczema with potential to outperform existing therapies like Dupixent.
- After eight weeks, 75% of participants taking soquelitinib achieved at least a 75% improvement in skin lesion severity (EASI 75), compared to 20% in the placebo group.
- Additionally, 33% of treated participants attained clear or almost clear skin after eight weeks, while none in the placebo group reached this outcome.
